Emergence of VIM-2 and IMP-15 carbapenemases and inactivation of oprD gene in carbapenem-resistant Pseudomonas aeruginosa clinical isolates from Lebanon

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4966-4970

  Al Bayssari, Charbel ^a,b   Diene, Seydina M ^a   Loucif, Lotfi ^a   Gupta, Sushim Kumar ^a   Dabboussi, Fouad ^b   Mallat, Hassan ^b   Hamze, Monzer ^b   Rolain, Jean Marc ^a  

^a AIX MARSEILLE UNIVERSITÉ   (France)

^b LEBANESE UNIVERSITY   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE IMP-15, PSEUDOMONAS AERUGINOSA; CARBAPENEM DERIVATIVE; OPRD PROTEIN, PSEUDOMONAS AERUGINOSA; PORIN; SPACER DNA; VIM-2 BETA-LACTAMASE;

ANTIBIOTIC RESISTANCE; BACTERIUM IDENTIFICATION; CHEMISTRY; CLASSIFICATION; DEFICIENCY; DRUG EFFECTS; GENETICS; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; LEBANON; METABOLISM; MICROBIOLOGY; MUTATION; PHYLOGENY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANTI-BACTERIAL AGENTS; BACTERIAL TYPING TECHNIQUES; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CARBAPENEMS; DNA, INTERGENIC; HOSPITALS; HUMANS; LEBANON; MUTATION; PHYLOGENY; PORINS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84905386978     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02523-13     Document Type: Article

References (21)

1. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front. Microbiol. 2:65. http://dx.doi.org/10.3389/fmicb.2011.00065.
2. Lee JY, Ko KS. 2012. OprD mutations and inactivation, expression of efflux pumps and AmpC, and metallo-β-lactamases in carbapenemresistant Pseudomonas aeruginosa isolates from South Korea. Int. J. Antimicrob. Agents 40:168-172. http://dx.doi.org/10.1016/j.ijantimicag.2012.04.004.
3. Wang J, Zhou JY, Qu TT, Shen P, Wei ZQ, Yu YS, Li LJ. 2010. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals. Int. J. Antimicrob. Agents 35:486-491. http://dx.doi.org/10.1016/j.ijantimicag.2009.12.014.
4. Seng P, Rolain JM, Fournier PE, La Scola B, Drancourt M, Raoult D. 2010. MALDI-TOF-mass spectrometry applications in clinical microbiology. Future Microbiol. 5:1733-1754. http://dx.doi.org/10.2217/fmb.10.127.
5. Kempf M, Bakour S, Flaudrops C, Berrazeg M, Brunel JM, Drissi M, Mesli E, Touati A, Rolain JM. 2012. Rapid detection of carbapenem resistance in Acinetobacter baumannii using matrix-assisted laser desorption ionization-time of flight mass spectrometry. PLoS One 7:e31676. http://dx.doi.org/10.1371/ journal.pone.0031676.
6. Yong D, Lee K, Yum JH, Shin HB, Rossolini GM, Chong Y. 2002. Imipenem-EDTA disk method for differentiation of metallo-betalactamaseproducing clinical isolates of Pseudomonas spp. and Acinetobacter spp. J. Clin. Microbiol. 40:3798-3801. http://dx.doi.org/10.1128/JCM.40.10.3798-3801.2002.
7. Touati M, Diene SM, Dekhil M, Djahoudi A, Racherache A, Rolain JM. 2013. Dissemination of a class I integron carrying VIM-2 carbapenemase in Pseudomonas aeruginosa clinical isolates from a hospital intensive care unit in Annaba, Algeria. Antimicrob. Agents Chemother. 57:2426-2427. http://dx.doi.org/10.1128/ AAC.00032-13.
8. Diene SM, L'homme T, Bellulo S, Stremler N, Dubus JC, Mely L, Leroy S, Degand N, Rolain JM. 2013. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France. Int. J. Antimicrob. Agents http://dx.doi.org/10.1016/j.ijantimicag.2013.06.001.
9. De Champs C, Poirel L, Bonnet R, Sirot D, Chanal C, Sirot J, Nordmann P. 2002. Prospective survey of beta-lactamases produced by ceftazidimeresistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob. Agents Chemother. 46:3031-3034. http://dx.doi.org/10.1128/AAC.46.9.3031-3034.2002.
10. Quale J, Bratu S, Gupta J, Landman D. 2006. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 50:1633-1641. http://dx.doi.org/10.1128/AAC.50.5.1633-1641.2006.
11. Samuelsen O, Toleman MA, Sundsfjord A, Rydberg J, Leegaard TM, Walder M, Lia A, Ranheim TE, Rajendra Y, Hermansen NO, Walsh TR, Giske CG. 2010. Molecular epidemiology of metallo-beta-lactamaseproducing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion. Antimicrob. Agents Chemother. 54:346-352. http://dx.doi.org/10.1128/ AAC.00824-09.
12. Tam VH, Schilling AN, Melnick DA, Coyle EA. 2005. Comparison of beta-lactams in counter-selecting resistance of Pseudomonas aeruginosa. Diagn. Microbiol. Infect. Dis. 52:145-151. http://dx.doi.org/10.1016/j.diagmicrobio. 2005.02.010.
13. Curran B, Jonas D, Grundmann H, Pitt T, Dowson CG. 2004. Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa. J. Clin. Microbiol. 42:5644-5649. http://dx.doi.org/10.1128/JCM.42. 12.5644-5649.2004.
14. Wolter DJ, Acquazzino D, Goering RV, Sammut P, Khalaf N, Hanson ND. 2008. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy. Clin. Infect. Dis. 46:e137-e141. http://dx.doi.org/10.1086/588484.
15. Sanbongi Y, Shimizu A, Suzuki T, Nagaso H, Ida T, Maebashi K, Gotoh N. 2009. Classification of OprD sequence and correlation with antimicrobial activity of carbapenem agents in Pseudomonas aeruginosa clinical isolates collected in Japan. Microbiol. Immunol. 53:361-367. http://dx.doi.org/10.1111/j. 1348-0421.2009.00137.x.
16. Cornaglia G, Giamarellou H, Rossolini GM. 2011. Metallo-β- lactamases: a last frontier for β-lactams? Lancet Infect. Dis. 11:381-393. http://dx.doi.org/10.1016/S1473-3099(11)70056-1.
17. Patel G, Bonomo RA. 2013. "Stormy waters ahead": global emergence of carbapenemases. Front. Microbiol. 4:48. http://dx.doi.org/10.3389/ fmicb.2013.00048.
18. Gilarranz R, Juan C, Castillo-Vera J, Chamizo FJ, Artiles F, Álamo I, Oliver A. 2013. First detection in Europe of the metallo-β-lactamase IMP-15 in clinical strains of Pseudomonas putida and Pseudomonas aeruginosa. Clin. Microbiol. Infect. http://dx.doi.org/10.1111/1469-0691.12248.
19. Quinones-Falconi F, Galicia-Velasco M, Marchiaro P, Mussi MA, Ballerini V, Vila AJ, Viale AM, Bermejo-Morales K, Limansky AS. 2010. Emergence of Pseudomonas aeruginosa strains producing metallo-betalactamases of the IMP-15 and VIM-2 types in Mexico. Clin. Microbiol. Infect. 16:126-131. http://dx.doi.org/10.1111/j.1469-0691.2009.02780.x.
20. Maatallah M, Cheriaa J, Backhrouf A, Iversen A, Grundmann H, Do T, Lanotte P, Mastouri M, Elghmati MS, Rojo F, Mejdi S, Giske CG. 2011. Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235. PLoS One 6:e25617. http://dx.doi.org/10.1371/journal.pone.0025617.
21. Sefraoui I, Berrazeg M, Drissi M, Rolain JM. 2013. Molecular epidemiology of carbapenem-resistant Pseudomonas aeruginosa clinical strains isolated from western Algeria between 2009 and 2012. Microb. Drug Resist. http://dx.doi.org/ 10.1089/mdr.2013.0161.